Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 6/2006

01-06-2006

Prognostic Significance of Residual Breast Disease and Axillary Node Involvement for Patients Who Had Primary Induction Chemotherapy for Advanced Breast Cancer

Authors: Pedro F. Escobar, MD, Rebecca J. Patrick, MA, Lisa A. Rybicki, MS, David Hicks, MD, David E. Weng, MD, PhD, Joseph P. Crowe, MD

Published in: Annals of Surgical Oncology | Issue 6/2006

Login to get access

Abstract

Background

We performed this study to determine the prognostic significance of clinical tumor size, pathologic measurement of residual tumor, and number of positive axillary nodes in the surgical specimen relative to overall survival for patients who underwent primary induction chemotherapy for advanced breast cancer.

Methods

Data, collected prospectively between 1997 and 2002, included clinical tumor-node-metastasis stage, age at diagnosis, hormone receptor status, type of preoperative chemotherapy, histological type, surgical procedure, pathologic measurement in centimeters of residual breast tumor, and the number of positive axillary nodes in the surgical specimen. Univariable correlates of residual breast disease were assessed by using the χ2 test. Recursive partitioning analysis was used to determine the prognostic significance of clinical tumor size, residual tumor size, and pathologic node involvement relative to overall survival. Survival was estimated by using the method of Kaplan and Meier and compared by using the log-rank test. A P value of < .05 was considered significant.

Results

Data were available for 85 patients with advanced breast cancer. Although univariable analysis identified increasing age, clinically involved axillary nodes, and a higher clinical tumor-node-metastasis stage as predictors of an increased risk of residual disease, recursive partitioning analysis identified more than three involved axillary nodes in the surgical specimen, with or without any measurable residual breast disease, as the most significant predictor of decreased survival (P < .001).

Conclusions

Pathologic axillary node involvement was the most significant predictor of decreased survival for patients who had undergone primary induction chemotherapy for advanced breast cancer.
Literature
1.
Adair F, Berg J, Joubert L, Robbins GF. Long term follow-up of breast cancer patients: the 30-year report. Cancer 1996;33:1145–50
2.
Hortobagyi GN. Comprehensive management of locally advanced breast cancer. Cancer 1990;66:1387–91PubMed
3.
Bear HD. Indications for neoadjuvant chemotherapy for breast cancer. Semin Oncol 1998;25:3–12PubMed
4.
Schwartz GF, Birchansky CA, Komarnicky LT, et al. Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer 1994;73:362–9PubMed
5.
Jakesz R. The ABCSG: comparison of pre- vs. postoperative chemotherapy in breast cancer patients—four-year results of Austrian Breast & Colorectal Cancer Study Group (ABCSG) trial 7 (abstract). Proc Am Soc Clin Oncol 2001;20:125
6.
Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15:2483–93PubMed
7.
Scholl SM, Fouquet A, Asselain B, et al. Primary versus adjuvant chemotherapy in premenopausal patients with tumors considered too large for breast conserving surgery: preliminary results of a randomised trial. Eur J Cancer 1994;30A:645–52CrossRefPubMed
8.
van der Hage JA, van de Velde CJH, Julien JP, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001;19:4224–37PubMed
9.
Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672–85PubMed
10.
Pierga JY, Mouret E, Dieras V, et al. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer 2000;83:1480–7CrossRefPubMed
11.
Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer. Significantly enhanced response with docetaxel. J Clin Oncol 2002;20:1456–66CrossRefPubMed
12.
Rajan R, Esteva FJ, Symmans WF. Pathologic changes in breast cancer following neoadjuvant chemotherapy: implications for the assessment of response. Clin Breast Cancer 2004;5:235–8PubMedCrossRef
13.
Colleoni M, Zahrieh D, Gelber RD, et al. Preoperative systemic treatment: prediction of responsiveness. Breast 2003;12:538–42CrossRefPubMed
14.
Penault-Llorca F, Bouchet MF, Amat S, et al. Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome. Int J Oncol 2003;22:1319–25PubMed
15.
Newman LA, Pernick NL, Adsay V, et al. Histopathologic evidence of tumor regression in the axillary lymph nodes of patients treated with preoperative chemotherapy correlates with breast cancer outcome. Ann Surg Oncol 2003;10:713–5CrossRef
16.
Arimappamagan A, Kadambari D, Srinivasan K, et al. Complete axillary conversion after neoadjuvant chemotherapy in locally advanced breast cancer: a step towards conserving axilla? Indian J Cancer 2004;41:13–7PubMed
17.
Kling KM, Ostrzega N, Schmit P. Breast conservation after induction chemotherapy for locally advanced breast cancer. Am Surg 1997;6:861–4
18.
Valagussa P. Prognostic factors in locally advanced noninflammatory breast cancer: long-term results following primary chemotherapy. Breast Cancer Res Treat 1990;15:137–47CrossRefPubMed
19.
Hortobagyi GN. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 1988;62:2507PubMed
20.
Zanbetti M. Combined sequential approach in locally advanced breast cancer. Ann Oncol 1999;10:305CrossRef
21.
Danforth DN, Zujewski J, O’Shaughnessy J, et al. Selection of local therapy after neoadjuvant chemotherapy in patients with stage III A, B breast cancer. Ann Surg Oncol 1998;5:150–8.CrossRefPubMed
22.
Schwartz GF, Cantor RI, Biermann WA. Neoadjuvant chemotherapy before definitive treatment for stage III carcinoma of the breast. Arch Surg 1987;122:1430–4PubMed
23.
Kuer HM, Newman LA, Fornage BD, et al. Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer. Ann Surg Oncol 1998;5:673–80CrossRef
24.
Gajdos C, Tartter P, Estabrook A, Gistrak MA, Jaffer S, Bleiweiss IJ. Relationship of clinical and pathological response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer. J Surg Oncol 2002;80:4–11CrossRefPubMed
25.
Krag DN, Single RM. Breast cancer survival according to number of nodes removed. Ann Surg Oncol 2003;10:1152–9CrossRefPubMed
26.
Lenert JT, Vlastos G, Mirza NQ, et al. Primary tumor response to induction chemotherapy as a predictor of histological status of axillary nodes in operable breast cancer patients. Ann Surg Oncol 1999;6:762–7CrossRefPubMed
27.
Low JA, Berman AW, Steinberg SM, et al. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol 2004;22:4067–77CrossRefPubMed
28.
Kaufmann M, von Minckwitz G, Smith R, et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 2003;21:2600–8CrossRefPubMed
Metadata
Title
Prognostic Significance of Residual Breast Disease and Axillary Node Involvement for Patients Who Had Primary Induction Chemotherapy for Advanced Breast Cancer
Authors
Pedro F. Escobar, MD
Rebecca J. Patrick, MA
Lisa A. Rybicki, MS
David Hicks, MD
David E. Weng, MD, PhD
Joseph P. Crowe, MD
Publication date
01-06-2006
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 6/2006
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/ASO.2006.07.024

Other articles of this Issue 6/2006

Annals of Surgical Oncology 6/2006 Go to the issue

Editorial

Adjuvant Treatment of Stage II Colon Cancer: Is There a True No-Chemotherapy Group?

Editorial

A Surgical Indication in Incurable Breast Cancer

Review

Current Issues in Adjuvant Treatment of Stage II Colon Cancer

OriginalPaper

Quality of Life After Hyperthermic Isolated Limb Perfusion for Locally Advanced Extremity Soft Tissue Sarcoma

OriginalPaper

Tumor Bed Boost Omission After Negative Re-Excision in Breast-Conservation Treatment

OriginalPaper

The Surgeon-Patient Interaction in Older Women With Breast Cancer: What Are the Determinants of a Helpful Discussion?